Celldex Therapeutics

Description

• Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
• 

  Headquarters:53 Frontage Road Suite 220, Hampton, New Jersey, United States

  More
• 

  Phone Number: +1 908-454-7120

• 

  Website: https://www.celldex.com

• 

  Employees:150

• 

  Revenue:$1 - 10M

• 

  Legal Name:Celldex Therapeutics

• Celldex Therapeutics's Social Media

  
• Is this data correct?

• |  NAICS Code: 541720  |

    NYSE: CLDX

  Show More